Tamtam Try Tamtam free
Kimberly-Clark logo

Kimberly-Clark account plan

Care essentials innovation sustainability

At a glance

Kimberly-Clark makes Huggies, Kleenex, Scott and Depend, and acquired Kenvue in November 2026; FY2025 net sales were $16.4 billion.

Kimberly-Clark, founded in 1872 and headquartered in the Dallas, Texas area, makes personal care and tissue products from fibers, nonwovens and absorbent materials under brands including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend and Pull-Ups, sold in more than 175 countries and territories. FY2025 continuing-operations net sales were $16.4 billion (-2.1%), operating profit $2.4 billion and adjusted EPS $6.12. It had approximately 36,000 employees and 74 production facilities in 30 countries at end-2025; Walmart represented approximately 16% of net sales. On November 2, 2026 it completed the acquisition of Kenvue (Listerine, Neutrogena, Tylenol), after placing its international tissue and professional business in a joint venture with Suzano on July 1, 2026.

Business units

Strategic priorities

Kenvue integration and synergies
Targeted $2.1 billion of annual synergies net of reinvestment, including about $1.9 billion of cost synergies within three years, phased about 40%/40%/20%; the Kenvue Integration Program carries approximately $3.1 billion of pre-tax charges through 2029.
Powering Care strategy
Three pillars: pioneering innovation through proprietary technology, an optimized margin structure across the good, better, best ladder, and an organization wired for growth. Innovation drove 78% of 2025 volume and mix growth.
Productivity and supply chain
The 2024 Transformation Initiative targets $3.0 billion of gross productivity and $200m of SG&A savings at approximately $1.5 billion of cost, now extended to end-2028; $2 billion is being invested in North America manufacturing, including a Warren, Ohio plant and a Beech Island, South Carolina distribution center.
Margin targets
Adjusted gross margin of at least 40% and adjusted operating margin of at least 18-20% before the end of the decade, with leverage below 2.0x net debt-to-EBITDA and a single-A rating.
Pure-play personal care and health
Pivot to higher-growth, higher-margin categories: PPE sold, about $650 million of private label exited, IFP moved to the Suzano joint venture, and Kenvue added.

Latest results

In Q3 2026 net sales were $4,134m (-0.4%), with organic sales -1.3% including an approximately 270 basis point headwind from the China social media disruption. Operating profit fell to $516m from $621m, including $106m of Kenvue acquisition costs; adjusted operating profit was $677m (-0.9%) and adjusted EPS from continuing operations $1.70 (+17.2%) on lower interest and tax. North America grew sales 0.9% while International Personal Care fell 2.8%. Nine-month net sales were $12,486m (+1.0%). The 2026 standalone outlook was reaffirmed: adjusted operating profit up mid-single digits and adjusted EPS from continuing operations up high single digits at constant currency.

Investments and deals

Kenvue acquisition
Completed November 2, 2026 for approximately $6.7 billion of cash and approximately 281.1 million Kimberly-Clark shares, funded partly by $4.9 billion of new senior notes.
Suzano joint venture
The IFP joint venture closed July 1, 2026, with Suzano paying approximately $1.3 billion for 51% and a pre-tax gain of approximately $1.4 billion.
North America manufacturing
$2 billion of investment in North America, including an advanced plant in Warren, Ohio and an automated distribution center at Beech Island, South Carolina.
Capital spending
Capital spending was $1.1 billion in 2025, with approximately $1.3 billion expected in 2026.
Kenvue Integration Program
Approximately $3.1 billion of charges through December 31, 2029, including supply chain network optimization (approximately $800m) and ERP and technology integration (approximately $600m).

Challenges and risks

China diaper disruption
False allegations about certain diaper brands spread on social media in China in Q2 2026, costing International Personal Care about 770 basis points of organic growth in Q3.
Input costs and tariffs
About $100m of incremental tariff costs hit 2025, and the Middle East conflict is expected to add approximately $250m of input costs in 2026 before mitigation.
Integration and debt
The Kenvue deal brings completion and integration risks, possible loss of customers or employees, and substantially higher indebtedness.
Private label and retailer concentration
Private label pressure in baby and family care, growing retailer concentration and dependence on Walmart, at approximately 16% of net sales.
Birth-rate declines and litigation
Falling birth rates in China, South Korea and the US pressure baby care volumes; Kenvue brings Tylenol and talc litigation, which management says due diligence assessed.

What leadership says

“The completion of our Kenvue transaction earlier this week marks a defining moment in the 154 year history of Kimberly-Clark.”

Mike Hsu, Chairman and CEO · Q3 2026 earnings release, November 5, 2026

“Our innovation pipeline has never been stronger.”

Mike Hsu, Chairman and CEO · Q4 2025 earnings remarks, January 27, 2026

“we are the best product and we're going to have the lowest cost.”

Mike Hsu, Chairman and CEO · CNBC Mad Money interview, November 7, 2025

“we still see generational value creation opportunity by putting these two companies together.”

Russ Torres, President and COO · Q4 2025 earnings Q&A, January 27, 2026

Where a supplier can help

ERP and systems integration
Tied to the Kenvue Integration Program and its approximately $600m ERP and technology integration bucket: integration, data migration and change-management services.
Supply chain automation
Tied to the productivity priority and the Warren, Ohio plant and Beech Island distribution center: automation, network optimization and manufacturing equipment suppliers.
G&A and procurement efficiency
Tied to the cost synergies, about 40% expected from G&A overheads: procurement, shared services and real estate consolidation offerings.
Consumer trust and social listening in China
Tied to the China social media disruption challenge: reputation monitoring and consumer communication tools address a demonstrated risk.
Input cost management
Tied to tariffs and Middle East input-cost pressure: sourcing, hedging and materials-substitution services support margin targets.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Kimberly-Clark?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Kimberly-Clark

What does Kimberly-Clark do?

It makes personal care and tissue products such as Huggies, Kleenex, Scott, Kotex and Depend, and since November 2026 also Kenvue's consumer health brands such as Listerine, Neutrogena and Tylenol.

What is Kimberly-Clark's revenue?

FY2025 continuing-operations net sales were $16.4 billion (-2.1%), with organic growth of 1.7%. Q3 2026 net sales were $4,134m.

How many employees does Kimberly-Clark have?

Approximately 36,000 at the end of 2025, including the IFP business, before the Kenvue acquisition.

Why did Kimberly-Clark buy Kenvue?

To build a health and wellness company with 10 billion-dollar brands, targeting $2.1 billion of annual synergies net of reinvestment and gaining scale in Western Europe and India.

Who leads Kimberly-Clark?

Michael D. Hsu is Chairman and CEO, Russell Torres is President and COO, and Nelson Urdaneta is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)